Execution Over Protection: Looking Beyond the Licensing-First Approach

Pre-Work (~35 minutes)

Read this before the session. The discussions will go deeper if you arrive with a position, even a tentative one.

---

The Core Argument

Here is the claim this lesson asks you to test:

For most research-based ventures, IP protection adds less competitive value than the time, money, and energy it costs, and a relentless focus on execution will build a more durable business faster.

That claim is not always true. The session is designed to find the edges where it breaks down.

But it is true more often than researchers expect. The default assumption in academic institutions: “protect first, then commercialise”, reflects the incentives of technology transfer offices and IP lawyers more than it reflects the realities of building a business. Those incentives are real and legitimate. They just aren’t your incentives.

---

What Protection Costs You

The costs of IP protection are visible on an invoice. The costs it imposes on your business are less obvious.

Time. A patent application takes 2–4 years to grant. During that window you may be legally restricted from disclosing the full details of your approach to potential customers, partners, or collaborators. Every month you’re protecting is a month a competitor who chose not to protect is talking to customers, iterating, and learning.

Disclosure. Patents require full public disclosure of your invention. Once filed, your approach is visible to any competitor who searches the literature, often before you’ve reached the market. The secrecy that provisional patents offer expires. Protection eventually means revealing.

Capital. International patent portfolios cost $15,000–$50,000+ to file, and require ongoing maintenance fees in each jurisdiction. For an early-stage venture with limited runway, that capital is not going toward product development, customer discovery, or hiring.

Rigidity. Patents protect a specific implementation. If the market tells you your approach needs to change, and it usually does, you may be protecting the wrong thing. Execution-first organisations can pivot. Patent-first organisations are anchored to what they filed.

Culture. NDAs, secrecy protocols, and IP restrictions create friction in research environments built on openness and collaboration. They can damage relationships with the academic ecosystem that produced your innovation in the first place.

---

What Execution Gains You

Execution-first organisations invest the same time and money in a different set of advantages:

Customer knowledge. Every week you’re talking to customers instead of filing paperwork is a week of learning. Who actually needs this? What are they willing to pay? What’s the workflow it fits into? This knowledge is tacit, personal, and genuinely hard for competitors to replicate.

Speed to market. First-mover advantage is real, though often overstated. What is reliably real is the compounding effect of getting feedback earlier. Organisations that ship faster improve faster.

Relationships. The customers, collaborators, and distribution partners you build relationships with early create genuine switching costs, not because of contracts, but because of trust, history, and integration. A competitor with a better product may still lose to you because your customers don’t want to retrain their staff and risk a transition.

Tacit knowledge. The deep, embodied expertise your team accumulates through doing, the failures that don’t appear in any paper, the workarounds that took six months to find, is genuinely difficult to replicate. It doesn’t appear in a patent application. It lives in people.

Revenue. Revenue funds the next iteration. A business generating $200K/year from early customers is more defensible than a business with a pending patent and no revenue.

---

What Protection Gains You

To argue fairly: here is what IP protection genuinely does well.

Legal standing. A patent gives you the same legal standing as a multinational corporation when defending against infringement. Without it, a well-funded competitor can replicate your approach and you have little recourse.

Licensing income. In some industries, the most economically rational path is not to build a business but to license your invention. Pharmaceutical compounds, certain semiconductor designs, and materials innovations often have more value as licences than as ventures. If this is your model, protection isn’t optional, it is the model.

Investor confidence. Many investors, particularly in life sciences and deep tech, require a defensible IP portfolio before they will write a cheque. The patent is not evidence of business viability; it is a signal that the underlying science has been validated and disclosed. In capital-intensive industries, this signal matters.

Freedom to operate. Knowing what you own, and what competitors own, lets you navigate the patent landscape without accidental infringement. A freedom-to-operate analysis is valuable even if you never file a patent yourself.

Deterrence. A portfolio of patents can deter competitors from entering your space, even if you never intend to litigate. The threat of expensive litigation is often enough.

---

What Execution Costs You

The honest account also includes what execution-first organisations give up.

Copycat vulnerability. If your innovation is easy to replicate, a software feature, a process improvement, a formulation, a well-funded competitor can build it in a fraction of the time it took you, without bearing your R&D costs. In markets where replication is cheap, protection matters more.

Platform risk. For software and digital tools, large platform companies can replicate your functionality and distribute it to their installed base in a product update. Execution moats can be erased by incumbents with distribution advantages. This is a structural risk that no amount of execution can fully mitigate without some form of protection or platform lock-in.

Capital access. As noted above, some investors simply will not invest without IP. If your path requires venture capital, and your investors require patents, execution-first is not a strategy, it is a disqualifier.

Pharma is different. In pharmaceutical development, the economics of clinical trials are so extreme, hundreds of millions of dollars, a decade of development, that no company would invest without the monopoly pricing that patent protection enables. Execution without protection in drug development is not a viable model. It is not even a coherent one.

---

Four Case Studies

These cases are deliberately in tension. Read all four and come to the session prepared to argue about them.

---

Case Study 1: Basecamp: The Execution Purist

37signals (now Basecamp) built project management software in 2004 with essentially no IP protection. They wrote blog posts, published books, and shared their methodology openly, including the business philosophy behind their product. They told competitors exactly how they built things.

By 2020 they had approximately 100,000 customers and tens of millions in annual revenue with fewer than 60 employees. In a market crowded with better-funded competitors, Asana, Monday.com, Trello, Jira, they remained profitable and independent.

Their moat was never a patent. It was an aesthetic, a philosophy, and a customer relationship. Competitors could read every word they published and still not replicate the specific culture, taste, and decision-making that made the product coherent.

What made this work: software, a small and targeted market, a strong product philosophy, direct sales. The product itself was the marketing.

Where this breaks down: Basecamp operates in a low-capital-expenditure market. Their “moat” requires a team with unusual taste and discipline. It is not transferable. Most people who try to copy their model don’t have the cultural raw material to execute it.

---

Case Study 2: Moderna vs. Pfizer/BioNTech: When Patents Are Existential

In 2022, Moderna sued Pfizer and BioNTech for infringing patents on mRNA vaccine technology. Moderna claimed Pfizer’s COVID-19 vaccine used modifications to mRNA that Moderna had invented and patented before the pandemic.

The stakes: billions of dollars in royalties, potential injunctions against vaccine manufacturing, and the precedent for who owns the foundational IP layer of what may be the most important vaccine platform in decades.

This is not a case where execution could substitute for protection. The capital required to develop an mRNA therapeutic, years of pre-clinical research, Phase I/II/III trials, regulatory approval, manufacturing scale-up, is only recoverable through pricing power that patents enable. Without exclusivity, a generic manufacturer could produce the same vaccine at cost the day after approval. The business model collapses.

What made protection essential: extreme capital requirements, commodity manufacturing once the formulation is known, regulatory pathway as the primary value gate, pricing power as the only cost-recovery mechanism.

Where this breaks down: Moderna’s patents didn’t prevent competition, they invited expensive litigation and generated enormous reputational risk during a public health crisis. The public perception of profiting from a pandemic-era patent has long-term brand consequences that execution-first companies rarely face.

---

Case Study 3: Spotify: Execution on Someone Else’s IP

Spotify built one of the most successful consumer technology companies of the past two decades without owning any of the content it delivers. Every song on the platform is licensed from rights holders. Spotify’s entire business model is built on top of other people’s IP.

Their competitive advantage was never the music. It was the discovery engine, the social graph, the interface, the playlist culture, and the frictionless experience of having almost everything in one place. They executed brilliantly on a product layer built on a licensed foundation.

And yet: Spotify has never been particularly profitable. The royalty obligations that enable their existence also compress their margins structurally. Apple Music, Amazon Music, and YouTube Music have distribution advantages that no amount of execution can fully overcome, they can afford to lose money on music indefinitely because music is one feature in a larger ecosystem.

What made this work: massive consumer market, high switching costs through playlists and recommendations, first-mover network effects in playlist culture, and superior UX at launch.

Where this breaks down: executing on licensed IP in a market with platform incumbents creates a structural ceiling. Spotify’s future depends on moving up the stack, into podcasts, audiobooks, tools for artists, to find margins that music licensing won’t provide. Execution alone, without owned IP or platform control, has limits.

---

Case Study 4: The CRISPR Patent War: Science, Priority, and Billions

Jennifer Doudna at UC Berkeley and Feng Zhang at the Broad Institute independently developed key elements of CRISPR-Cas9 gene editing within months of each other. Both institutions filed patents. The dispute over who invented what, and who filed first, consumed years of legal process and tens of millions in legal fees.

The outcome matters because CRISPR licences are worth enormous sums. Whoever controls the foundational patents controls the licensing revenue from every therapeutic, agricultural, and industrial application of the technology. In this case, both institutions eventually secured rights to different application domains.

But here is the question the case raises: what happened to the science while the lawyers argued?

Researchers continued to publish, iterate, and build applications of CRISPR through the entire dispute. The patent battle affected the business layer, who could commercialise, on what terms, but had essentially no effect on the scientific progress. The execution of the research was entirely decoupled from the IP dispute.

What this shows: patent disputes are expensive, slow, and largely fought at the institutional rather than the researcher level. The researchers who did the science mostly kept working. The question of who owned the IP was a question for technology transfer offices and law firms, not for the people doing the actual work.

---

Counter-Examples: When the Execution Argument Fails

The case for execution-first is strong. It is not universal. Here are four cases where it breaks down, chosen specifically because they challenge the lesson’s main argument.

---

Counter-Example 1: Napster vs. Spotify: Execution Without Licensing Is Not Enough

Napster launched in 1999 and within 18 months had 80 million users, one of the fastest consumer technology adoptions in history. By every execution metric, it was extraordinary: product-market fit was instant, growth was viral, and the user experience solved a genuine problem at massive scale.

Napster was shut down in 2001.

Not because of poor execution. Because it had no legal right to distribute the music it was distributing. The courts found it liable for contributory copyright infringement. No amount of product quality, growth, or user love could survive that structural vulnerability.

Spotify launched in 2008 with a nearly identical value proposition, music, on demand, any device, but spent two years before launch negotiating licensing agreements with every major label. They launched slowly, in limited markets, because they were building legal foundations before building user base. By conventional execution logic, that was costly delay. In reality, it was the only viable path.

What this shows: execution without a legal right to operate is not a moat, it is a liability. In markets where your core input is owned by someone else (music, film, pharmaceutical compounds, proprietary datasets), IP isn’t optional. It’s the ante.

---

Counter-Example 2: Dyson: Protection Enabled Execution

James Dyson spent three years and 5,127 prototypes developing his cyclone vacuum technology before filing patents in the early 1980s. He then spent nearly two decades in patent licensing disputes with major manufacturers who copied his design.

The conventional narrative is that Dyson won through design and brand execution. That is partly true. But it obscures something important: Dyson’s willingness to invest in manufacturing, marketing, and global expansion was made possible by the patent protection that gave him a window of exclusivity. Without that window, competitors with vastly greater manufacturing scale could have commoditised the cyclone vacuum before Dyson had built the brand to survive it.

His patents did not prevent all copying, eventually they couldn’t. But they bought time. Time to establish the brand, build distribution, and create the customer loyalty that ultimately became the real moat. The IP was not the destination; it was the runway.

What this shows: execution moats often take years to build. In that window, IP protection can be the thing that keeps a better-resourced competitor from erasing you before your execution advantage has time to compound. Protection and execution are not always in competition, sometimes one creates the conditions for the other.

---

Counter-Example 3: The Generic Drug Cliff: Execution Means Nothing at Patent Expiry

When Pfizer’s Lipitor, the best-selling drug in pharmaceutical history, lost patent protection in 2011, its revenue dropped by roughly 70% within a year. Not because Pfizer had executed poorly. Not because a competitor had a better product. Simply because generic manufacturers could now produce an identical compound at a fraction of the cost.

Pfizer had spent decades building manufacturing excellence, sales networks, physician relationships, and brand recognition. None of it meaningfully softened the cliff. In the pharmaceutical market, the patent is the business model. When it expires, the pricing power that justifies the entire R&D investment evaporates almost immediately.

This is the starkest possible demonstration that execution moats, without IP protection, cannot survive in markets where the core product can be exactly replicated. “Exactly replicated” is the key phrase. In most software and services markets, exact replication is impossible because the product is inseparable from the people who build and maintain it. In pharmaceuticals, the active compound can be replicated perfectly by anyone with the right chemistry capability.

What this shows: the execution-first argument relies on replication being hard. When replication is easy, or eventually becomes easy, execution moats erode. The relevant question is not “can they copy me today?” but “can they copy me in five years, when I need the business to still be viable?”

---

Counter-Example 4: Amazon One-Click: A Patent as a Competitive Weapon

In 1999, Amazon patented the “one-click” purchase, the ability to buy something online with a single click using stored payment and shipping information. The patent was widely mocked as trivially obvious. It was also ruthlessly effective.

Amazon used it to block Barnes & Noble from using a similar feature for years, forced Apple to license it (at reportedly significant cost), and held competitors to a higher-friction checkout experience during the years when online retail trust was being established. Removing checkout friction during that critical window compounded into a meaningful conversion rate advantage.

The one-click patent did not save Amazon. Their execution, logistics, Prime, marketplace, AWS, built the actual business. But the patent created an artificial moat during a window when customer trust in e-commerce was fragile and checkout friction genuinely affected purchase decisions. It was worth, by any reasonable estimate, considerably more than it cost to file.

What this shows: even in software and digital markets, where execution moats are supposed to dominate, a precisely targeted patent at the right moment on the right feature can create durable competitive advantage. The argument is not “patents never matter in software.” It is “most software patents don’t matter.” The strategic question is whether yours is in the minority that does.

---

Reflection Prompts

Bring your thinking on these to the session. There are no right answers.

1. Which of the four case studies most closely resembles your field, not your specific work, but the structural economics of your research area? Why?
2. If a well-funded competitor started working on something similar to your current research today, what would they actually need to replicate you? How long would it take?
3. Is there something you’re currently keeping confidential that might be more valuable if it were public? What’s the argument for and against disclosure?

---

Session

Facilitator guide. 60 minutes. Participants should have read all four case studies.

---

Before You Begin

This session works best when participants disagree with each other. If the room quickly converges on “execution is better,” push back. If they converge on “protection is always necessary,” push back the other way. The nuance is the point.

Have the four case study names visible on a whiteboard or slide throughout: Basecamp · Moderna · Spotify · CRISPR.

---

Discussion 1: The Copycat Test (10 min)

Pairs. Purpose: make the threat model concrete before discussing the response.

Prompt:

Imagine someone in your field, a well-funded competitor, a large company, or a foreign government-backed research programme, decided today to replicate your work. What would they actually need?

Push participants to be specific: people, equipment, data, time, relationships, institutional access. Then ask: of those things, which ones can a patent prevent them from acquiring?

Share-back: one person per pair names the thing on their list that surprised them most.

---

Discussion 2: The Cost Accounting Argument (10 min)

Small groups of 3–4. Purpose: challenge the assumption that protection is “responsible” and execution is “risky.”

Prompt:

Basecamp chose not to protect. Moderna had to protect. Spotify built on licensed IP. CRISPR forced protection through institutional incentives.

For your research area: what does protecting cost you, and what does it cost you to skip it? Be specific about both sides of the ledger.

Facilitator note: push groups to assign rough magnitudes. “$30K in filing costs vs. six months of a competitor’s head start” is more useful than abstract lists.

Share-back: one cost from each side of the ledger, per group.

---

Discussion 3: The Customer Doesn’t Care (15 min)

Plenary. This is often the most disorienting discussion for researchers. Take time here.

Open with: “Does your customer care who owns the patent?”

In most markets, the answer is no. Customers care whether the product works, whether it integrates with their workflow, whether the team will support them, and whether the price is fair. The patent is invisible to them.

There are exceptions: regulated markets where IP status affects approval pathways, procurement processes that require IP indemnification, and markets where brand trust is built on innovation credentials. Name these explicitly and ask whether they apply.

Then push to the sharper question: “What does your customer actually value that a competitor would struggle to replicate, not because of a patent, but because of what it would require them to do?”

This is where execution moats show up: a team that understands the biology at a level competitors don’t yet have, a dataset that took five years to assemble, a clinical relationship network built on trust, a workflow integration that would require months of redevelopment.

Close with: “If you were advising a first-time founder in your field, what would you tell them to invest in first, protection or execution? What would make you change that advice?”

---

Discussion 4: The Conflicting Cases (15 min)

Assign each small group one case study pair, Basecamp vs. Moderna, or Spotify vs. CRISPR. Ask them to argue both sides.

Prompt:

Your case study pair represents two different answers to the same question. What structural features of each business made one approach right and the other wrong? Could either company have chosen the other path?

This is the analytical core of the session. What participants should find: the right approach is not a philosophy but a function of capital requirements, replication cost, customer structure, and market dynamics. Basecamp could not have chosen Moderna’s path even if it had wanted to, and vice versa.

Share-back: one structural factor per group that most clearly explained the divergence.

---

Discussion 5: Your Honest Assessment (10 min)

Return to plenary. This connects the theory back to each participant’s actual situation.

Ask each participant to answer out loud or in a shared doc: “Based on this session, am I in a situation where protecting first makes structural sense, or where executing first is the better bet? What’s the one piece of evidence that most influenced that answer?”

Facilitator: don’t let participants say “it depends” without specifying what it depends on. The goal is a tentative position, not a final answer.

Close: “Your challenge this week asks you to write the moat argument, the honest account of what actually protects your work, whether or not it’s a patent. That’s the document an investor, a partner, or a competitor would want to understand. Writing it for yourself is the first step.”

---

Challenge (~45 min)

Produce something you can use. This feeds into mentoring check-ins and 90-day planning.

---

Your Moat Map

Work through this for one piece of research, technology, or expertise you’re actively developing.

Part 1, The Replication Analysis

List everything a well-funded competitor would need to replicate your work:

• Scientific or technical knowledge
• Equipment or infrastructure
• Data, samples, or proprietary materials
• Relationships (clinical, industrial, regulatory)
• People and tacit expertise
• Time

For each item, estimate: how long would it take them to acquire it, and how much would it cost? Mark each one: easy to replicate / hard to replicate / essentially irreplicable.

Part 2, The Moat Candidates

From your list, identify the 2–3 things that are hardest to replicate. For each, decide which category it falls into:

• IP-based: protected by a patent, trade secret, or copyright
• Execution-based: the result of accumulated doing: speed, iteration, tacit knowledge
• Relationship-based: trust, access, and history that takes years to build
• Structural: first-mover network effects, switching costs, platform position

Part 3, The Honest Trade-off

Answer these directly:

1. If you spent the next $30,000 on patent filing instead of product development, customer discovery, or hiring, would your competitive position be stronger or weaker in 18 months?
2. What is the thing you’re most tempted to protect that you should probably just publish or open source? What’s stopping you?
3. What is the thing you’re most tempted to leave unprotected that probably needs protecting? What’s stopping you?

Part 4, The Moat Argument

Write one paragraph, 100–150 words, as if you’re answering the question an investor just asked: “What stops a well-resourced competitor from copying you?”

Do not mention patents unless patents are genuinely your answer. If your moat is execution, say so. If it’s relationships, say so. If you don’t have a convincing moat yet, say that too, that’s an honest and useful starting point.

Bring this to your next mentoring check-in.

---

Key Concepts Reference

Execution moat: competitive advantage derived from superior speed, quality, iteration, or accumulated know-how rather than legal protection. Often more durable than IP in fast-moving markets; more fragile in capital-intensive ones.

Replication cost: how much time and money a competitor would need to reproduce your capability. High replication cost is a genuine moat regardless of patent status.

Tacit knowledge: knowledge embedded in people and practice that cannot be fully written down or transferred through documentation. The accumulated expertise of a team that has done something for years is often the hardest thing for a competitor to replicate.

Switching costs: the friction a customer faces when moving from your product to a competitor’s. Can be technical (integrations, data formats), relational (trust, training, history), or contractual.

Platform risk: the vulnerability of a product that competes inside a platform controlled by a larger player. The platform owner can replicate your features at near-zero marginal cost and distribute them to their user base in a product update.

Freedom to operate (FTO): an analysis of whether you can build and sell your product without infringing existing patents. Useful even if you never file a patent of your own.

Licensing model: a business model in which value is captured through charging others for the right to use your IP, rather than through building and selling a product or service. Requires strong IP protection; often more appropriate in capital-intensive industries than in software or services.